In ₹ Crore except Per Share Latest Annual | AAREYDRUGS FY26 | NECLIFE FY26 | NATCAPSUQ FY26 | MEDICAMEQ FY26 | Peer Median | |
|---|---|---|---|---|---|---|
| Valuation — at last close | ||||||
| P/E | 68.34× | — | — | ◆ 41.83× | 41.83× +63% | |
| P/B | 1.80× | ◆ 0.40× | — | 1.49× | 0.94× +91% | |
| EV/EBITDA | 44.46× | ◆ -3.59× | — | 21.75× | 9.08× +390% | |
| Market Cap | ₹270 Cr | ₹231 Cr | — | ₹410 Cr | ₹320 Cr -16% | |
| Growth | ||||||
| Revenue CAGR 3Y | ◆ 96.26% | -81.73% | — | 11.97% | -34.88% +376% | |
| Revenue CAGR 5Y | — | -64.04% | — | — | -64.04% | |
| Net Income CAGR 3Y | ◆ 100.20% | — | — | -12.71% | -12.71% +888% | |
| Revenue YoY (latest Q) | -56.34% | -99.99% | 7.76% | ◆ 11.27% | 7.76% -826% | |
| Net Income YoY (latest Q) | -25.36% | ◆ 75.65% | -2.93% | 15.35% | 15.35% -265% | |
| Profitability | ||||||
| EBITDA Margin | 1.52% | — | -0.83% | ◆ 9.90% | 4.54% -66% | |
| Net Income Margin | 0.84% | -3152.45% | -13.17% | ◆ 4.95% | -13.17% +106% | |
| Return on Common Equity | 2.64% | -50.30% | -7.27% | ◆ 3.50% | -7.27% +136% | |
| Return on Capital Employed | 2.84% | -10.25% | -6.42% | ◆ 4.35% | -6.42% +144% | |
| Return on Assets | 1.33% | -47.12% | -5.81% | ◆ 2.63% | -5.81% +123% | |
| Credit & Quality | ||||||
| Total Debt/Equity | 0.33× | ◆ 0.00× | 0.49× | 0.17× | 0.17× +94% | |
| Interest Coverage | 0.86× | -1.69× | -1.71× | ◆ 3.54× | -1.69× +151% | |
| Scale — latest FY | ||||||
| Revenue / Total Income | ₹472 Cr | ₹0 Cr | ₹187 Cr | ₹198 Cr | ₹187 Cr +152% | |
| Net Income | ₹4 Cr | −₹293 Cr | −₹24.7 Cr | ₹9.8 Cr | −₹24.7 Cr +116% | |
| Total Assets | ₹297 Cr | ₹622 Cr | ₹424 Cr | ₹372 Cr | ₹424 Cr -30% | |
| EPS | ₹1.39 | ₹-13.4 | ₹-23.84 | ₹7.22 | ₹-13.4 +110% | |
| Book Value per Share | ₹52.86 | ₹29.97 | ₹225.99 | ₹203.17 | ₹203.17 -74% | |